Abstract: Advantage is taken of macrolide antibiotics' complexation with free cholesterol to yield fluorescent complexes to determine the levels of free cholesterol, total cholesterol, or lecithin: cholesterol acyl transferase (LCAT) in serum or plasma or fractions thereof.

Abstract: A cardiac troponin I ultra-sensitive detection reagent kit, a preparation method, and a detection method. The reagent kit comprises at least one first anti-cardiac troponin I antibody marked with a trace marker and at least one second anti-cardiac troponin I antibody coated on magnetic microspheres, the first anti-cardiac troponin I antibody and cardiac troponin I binding site being different from the second anti-cardiac troponin I antibody and cardiac troponin I binding site. The reagent kit may further comprise a diluent capable of significantly reducing non-specific binding in a detection process, so as to further increase the detection accuracy and sensitivity. The method using the reagent kit to detect cardiac troponin I sensitively and accurately detects the amount of cardiac troponin I in a sample, and provides more timely and reliable information for the early diagnosis and treatment of AMI.

Abstract: The present invention relates to a beef-specific age determination marker containing the p21 protein, to an antibody specifically bound to bovine p21 protein, to a beef-specific age determination kit containing the antibody which is specifically bound to the bovine p21 protein, and to a method which involves detecting the bovine p21 protein through an antigen-antibody binding reaction using the antibody which is specifically bound to the bovine p21 protein serving as a beef-specific age determination marker in the muscle tissue of beef, so as to determine the age of the beef. According to the present invention, the p21 protein is significantly greatly expressed in the muscle tissue of beef, the age of which is lower than 30 months, and is hardly expressed in the muscle tissue of beef, the age of which is greater than 30 months, and thus can be valuably used as a beef-specific age determination marker.

Abstract: An electrochemiluminescence method of detecting an analyte in a liquid sample and a corresponding analysis system. An analyte in a liquid sample is detected by first providing a receptacle containing a fluid comprising protein coated magnetic microparticles to a stirring unit. Stirring of the fluid is necessary since the density of the microparticles is usually higher than the density of the buffer fluid. Thus the microparticles tend to deposit on the bottom of the receptacle leading to an aggregation of the microparticles because of weak interactions. To obtain representative measurements a homogeneous distribution of the microparticles in the buffer fluid is necessary to ensure a constant concentration of microparticles for each analysis cycle. It is further necessary to provide disaggregation of the microparticles, which is also realized by stirring the fluid. Stirring is conducted with a rotational frequency that is adapted to the amount of fluid to be stirred.

Abstract: Aspects of the present disclosure relate to binding agents (e.g., antibodies and antigen binding fragments) that bind soluble fms-like tyrosine kinase 1 (sFlt1) in an isoform specific manner. In some embodiments, immunological assay methods utilizing isoform-specific antibodies or antigen binding fragments that bind sFlt1 isoforms are provided for assessing biological samples obtained from pregnant subjects, e.g., for purposes of evaluating preeclampsia status in the subject.

Abstract: Disclosed is an invention in the field of conducting an immunoassay of 25(OH) vitamin D in blood or blood components, notably serum or plasma. The invention employs a perfluoro alkyl acid, or a salt thereof, to release 25(OH) vitamin D from vitamin D binding protein. Thereafter the binding protein comprising the 25-OH vitamin D is subjected to a competitive binding assay with a labeled vitamin D compound.

Abstract: The invention relates to diagnostics, namely to a reagent kit, a rapid method and a device for detecting the fact of chronic, ischemia-linked brain pathology. A special feature of the invention is the use of an immunoactive hybrid peptide produced as a product of two fragments of the NMDA neuroreceptor subunits. A device is described that allows quick and convenient testing of autoantibodies in the patient's blood that recognize the hybrid peptide. The method of detection of autoantibodies is based on the principle of lateral flow immunochromatography. The invention can be used for prophylactic medical examination (screening of chronic ischemia-linked brain lesions), to detect decompensated chronic cerebral ischemia at the prehospital stage by general practitioners or neurologists, as well as in neurosurgery and sports medicine for diagnostics of delayed cerebral ischemia in persons with craniocerebral injury.

Abstract: The application describes methods for determining the particle number and/or molar mass of lipoprotein(a) subform(s) in a biological sample using enzyme linked immunosorbent assay (ELISA). The methods described herein significantly improve lipoprotein ELISA methods and devices capable of quantifying particle numbers and population mass of Lp(a) particles. This technology offers a method for the efficient and cost-effective measurement of specific Lp(a) in a rapid, low-cost format, rather than limited measurement of Lp(a) concentration in patient tissues. The ability to measure the particle number and/or molar mass of lipoprotein(a) subform(s) in a biological sample also provides a useful diagnostic tool for assessing cardiovascular risk in a subject.

Abstract: A test device for detection and visual identification of a specific analyte in a liquid sample such as a bodily fluid is disclosed. The device includes a collection container, a test strip affixed to an interior surface of the collection container, and a removable protective strip adhered over the test strip. The protective strip is configured to be removed from contact with the test strip after the liquid sample has been collected in order to prevent unnecessary exposure and/or contamination of the test strip. In certain embodiments, the protective strip may be removed from the contact with the test strip when the collection container is in a sealed configuration. In other embodiments, the protective strip may be dissolvable when placed in contact with the desired liquid sample. An assay specific to the anticipated analyte may be provided on the test strip.

Abstract: The present invention is directed to a novel method to multiplex long lifetime fluorescent dyes using time-resolved fluorescence (TRF) detection. A combination of spectral and temporal differences in fluorescence emission is used to enhance the ability to separate signals in an assay from multiple dyes. Multiplexed TRF detection apparatuses and systems configured for performing all or part of any of the methods disclosed herein are also provided, particularly apparatuses and systems incorporating cartridge-based multi-mode readers.

Abstract: Disclosed is a novel method for measuring haemagglutinin of an influenza virus, which can construct an assay system in a shorter period of time than a sandwich immunoassay method using two kinds of anti-haemagglutinin antibodies. The method for measuring haemagglutinin of an influenza virus is achieved by a sandwich immunoassay method comprising sandwiching the haemagglutinin between a lectin which binds to the haemagglutinin but does not bind to an antibody, and an anti-haemagglutinin antibody which undergoes antigen-antibody reaction with the haemagglutinin.

Abstract: A device and method for detecting bacteria in a sample can include an optically transparent substrate and a phage that is known to react with the bacteria being detected. The phage can be tagged with a fluorescent tag such as DAPI or SBYR® Gold cyanine dye. Once fluorescently tagged, the phage-substrate combination can be illuminated with a light source, at a wavelength that corresponds to an excitation wavelength for the fluorescent tag to establish a baseline intensity for the device. The device can then be exposed to the sample and illuminated to establish a test intensity. The bacteria to be detected can be deemed as being present if the test intensity is less than the baseline intensity.

Abstract: An object of the present invention is to provide a method of detecting a specific tissue or cell in a sample tissue section and accurately specifying both the position(s) and amount of a biological substance of interest that is expressed on the specific tissue or cell.

Abstract: The present invention intends to provide an immunochromatographic test piece that makes it possible to achieve both highly sensitive detection of a substance to be detected and a simple test piece structure, which are usually difficult to be made compatible with each other.

Abstract: The application describes methods for determining the concentration and/or particle number of a lipoprotein(a) subform in a biological sample using capillary isotachophoresis laser induced fluorescence (CE-ITP-LIF) and compositional analysis of lipoprotein(a) particles. The ability to measure the concentration and/or particle number of a lipoprotein(a) subform in a biological sample provides a useful diagnostic tool for assessing cardiovascular risk in a subject.

Abstract: The present invention relates to an enlarged sample of interest for microscopy and methods for enlarging a sample of interest and the optical imaging of a sample of interest with resolution better than the classical microscopy diffraction limit, by synthesizing a swellable polymer network within a sample, it can be physically expanded, resulting in physical magnification.

Abstract: The present invention provides a test kit capable of rapid and highly sensitive detection. The test kit is provided with a first member, which contains a region in which is held a labeling substance with a label immobilized on a substance that specifically binds with a substance to be detected, and a second member, which has a detection zone where the labeling substance is captured through the substance to be detected, which is connected downstream of the first member in the developing direction, and which allows the labeling substance contained in a liquid sample that flows in from the first member, to develop into the detection zone.

Abstract: The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.

Abstract: A panel for monitoring levels of biomarkers, including an assay having at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test. A method of monitoring an individual's health, by collecting a sample from the individual, applying the sample to an assay panel, performing at least one inflammation monitoring test, at least one oxidative stress monitoring test, and at least one antioxidant activity monitoring test in the panel, and determining levels of biomarkers related to inflammation, oxidative stress, and antioxidant activity and therefore providing information regarding the individual's relative health and/or risk of developing one or more diseases.

Abstract: The present invention aims to present methods to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis by using a protein or its partial peptide that differs in presence or absence, or in quantity between healthy human subjects and patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis or between patients with fatty liver and nonalcoholic steatohepatitis and further aims to present biomarkers comprising said protein and said partial peptide to be used to detect nonalcoholic fatty liver disease including nonalcoholic steatohepatitis. Specifically, 35 kDa protein fragment consisting of amino acid sequence expressed by Sequence No. 2 and its partial peptide consisting of amino acid sequence expressed by Sequence No. 3 (including its glycated form) of inter-alpha-trypsin inhibitor heavy chain H4 precursor consisting of amino acid sequence expressed by Sequence No.